167 related articles for article (PubMed ID: 18761404)
1. Trifluralin liposomal formulations active against Leishmania donovani infections.
Carvalheiro M; Jorge J; Eleutério C; Pinhal AF; Sousa AC; Morais JG; Cruz ME
Eur J Pharm Biopharm; 2009 Feb; 71(2):292-6. PubMed ID: 18761404
[TBL] [Abstract][Full Text] [Related]
2. Hemisynthetic trifluralin analogues incorporated in liposomes for the treatment of leishmanial infections.
Carvalheiro M; Esteves MA; Santos-Mateus D; Lopes RM; Rodrigues MA; Eleutério CV; Scoulica E; Santos-Gomes G; Cruz ME
Eur J Pharm Biopharm; 2015 Jun; 93():346-52. PubMed ID: 25936854
[TBL] [Abstract][Full Text] [Related]
3. Antileishmanial effect of free and encapsulated sinefungin against Leishmania donovani infections in BALB/c mice.
Neal RA; Iwobi MV; Robert-Gero M
C R Acad Sci III; 1989; 308(18):485-8. PubMed ID: 2508995
[TBL] [Abstract][Full Text] [Related]
4. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
Everlien H; Hockertz S
Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
[TBL] [Abstract][Full Text] [Related]
5. Lipid-based nanoformulations of trifluralin analogs in the management of Leishmania infantum infections.
Lopes RM; Pereira J; Esteves MA; Gaspar MM; Carvalheiro M; Eleutério CV; Gonçalves L; Jiménez-Ruiz A; Almeida AJ; Cruz ME
Nanomedicine (Lond); 2016 Jan; 11(2):153-70. PubMed ID: 26651236
[TBL] [Abstract][Full Text] [Related]
6. Leishmania donovani: pilot study for evaluation of therapeutic effects of inosine analogs against amastigotes in vitro and in vivo.
Morishige K; Aji T; Ishii A; Yasuda T; Wataya Y
Exp Parasitol; 1995 Jun; 80(4):665-71. PubMed ID: 7758547
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani.
Nakayama H; Desrivot J; Bories C; Franck X; Figadère B; Hocquemiller R; Fournet A; Loiseau PM
Biomed Pharmacother; 2007; 61(2-3):186-8. PubMed ID: 17360145
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic evaluation of free and liposome-loaded furazolidone in experimental visceral leishmaniasis.
Tempone AG; Mortara RA; de Andrade HF; Reimão JQ
Int J Antimicrob Agents; 2010 Aug; 36(2):159-63. PubMed ID: 20554161
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice.
Pal S; Ravindran R; Ali N
Antimicrob Agents Chemother; 2004 Sep; 48(9):3591-3. PubMed ID: 15328135
[TBL] [Abstract][Full Text] [Related]
10. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs.
Garnier T; Mäntylä A; Järvinen T; Lawrence J; Brown M; Croft S
J Antimicrob Chemother; 2007 Oct; 60(4):802-10. PubMed ID: 17715126
[TBL] [Abstract][Full Text] [Related]
11. Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin.
Proulx ME; Désormeaux A; Marquis JF; Olivier M; Bergeron MG
Antimicrob Agents Chemother; 2001 Sep; 45(9):2623-7. PubMed ID: 11502539
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of trifluralin analogues as antileishmanial agents.
Esteves MA; Fragiadaki I; Lopes R; Scoulica E; Cruz ME
Bioorg Med Chem; 2010 Jan; 18(1):274-81. PubMed ID: 19926293
[TBL] [Abstract][Full Text] [Related]
13. Fluorinated rhodacyanine (SJL-01) possessing high efficacy for visceral leishmaniasis (VL).
Yang M; Arai C; Bakar Md A; Lu J; Ge JF; Pudhom K; Takasu K; Kasai K; Kaiser M; Brun R; Yardley V; Itoh I; Ihara M
J Med Chem; 2010 Jan; 53(1):368-73. PubMed ID: 19894726
[TBL] [Abstract][Full Text] [Related]
14. Fucoidan cures infection with both antimony-susceptible and -resistant strains of Leishmania donovani through Th1 response and macrophage-derived oxidants.
Kar S; Sharma G; Das PK
J Antimicrob Chemother; 2011 Mar; 66(3):618-25. PubMed ID: 21393231
[TBL] [Abstract][Full Text] [Related]
15. Selection and phenotype characterisation of sitamaquine-resistant promastigotes of Leishmania donovani.
Bories C; Cojean S; Huteau F; Loiseau PM
Biomed Pharmacother; 2008 Mar; 62(3):164-7. PubMed ID: 18249083
[TBL] [Abstract][Full Text] [Related]
16. Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations.
Papagiannaros A; Bories C; Demetzos C; Loiseau PM
Biomed Pharmacother; 2005 Dec; 59(10):545-50. PubMed ID: 16325367
[TBL] [Abstract][Full Text] [Related]
17. Liposomal resiquimod for the treatment of Leishmania donovani infection.
Peine KJ; Gupta G; Brackman DJ; Papenfuss TL; Ainslie KM; Satoskar AR; Bachelder EM
J Antimicrob Chemother; 2014 Jan; 69(1):168-75. PubMed ID: 23956375
[TBL] [Abstract][Full Text] [Related]
18. Antiparasitic activity of a triphenyl tin complex against Leishmania donovani.
Raychaudhury B; Banerjee S; Gupta S; Singh RV; Datta SC
Acta Trop; 2005 Jul; 95(1):1-8. PubMed ID: 15896700
[TBL] [Abstract][Full Text] [Related]
19. Targeting of piperine intercalated in mannose-coated liposomes in experimental leishmaniasis.
Raay B; Medda S; Mukhopadhyay S; Basu MK
Indian J Biochem Biophys; 1999 Aug; 36(4):248-51. PubMed ID: 10650726
[TBL] [Abstract][Full Text] [Related]
20. Engima of therapeutic failure in visceral leishmaniasis.
Arya SC
J Assoc Physicians India; 1993 Mar; 41(3):155-8. PubMed ID: 8226600
[No Abstract] [Full Text] [Related]
[Next] [New Search]
